Global Arthritis Monoclonal Antibodies Market Size, Share, and COVID-19 Impact Analysis, Russia-Ukraine War Impact, Tariff Analysis, By Type (Humira, Remicade, Enbrel, Rituxan, and Others), By Application (Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Gobal Arthritis Monoclonal Antibodies Market Summary, Size & Emerging Trends

According to Spherical Insights, the Global Arthritis Monoclonal Antibodies Market Size is Expected to Grow from USD 57.85 Billion in 2024 to USD 129.65 Billion by 2035, at a CAGR of 7.61% during the forecast period 2025-2035. The increasing prevalence of autoimmune diseases and advancement in biotechnology & genetic engineering are the key growth drivers for the global arthritis monoclonal antibodies market.

Get more details on this report -

Request Free Sample PDF

Key Market Insights

• North America is expected to account for the largest share in the Arthritis Monoclonal Antibodies market during the forecast period.
• In terms of type, the Humira segment is projected to lead the Arthritis Monoclonal Antibodies market in terms of type throughout the forecast period
• In terms of applications, the rheumatoid arthritis segment captured the largest portion of the market.

 

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 57.85 Billion
• 2035 Projected Market Size: USD 129.65 Billion
• CAGR (2025 to 2035): 7.61%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

 

Arthritis Monoclonal Antibodies Market

The arthritis monoclonal antibodies market is the industry for engineered protein drugs used for treating inflammatory arthritis conditions such as rheumatoid arthritis. Monoclonal antibody medications are used if other rheumatoid arthritis treatments aren’t effective. Monoclonal antibodies work by the principle of binding to an antigen protein on the surface of a cell, which helps in protecting from exposure. With an increasing awareness about biologics as precision medicine, there is an increasing demand for monoclonal antibodies for targeting arthritis.

 

Arthritis Monoclonal Antibodies Market Trends

• Use of advanced biotechnology for enhancing efficacy and reducing side effects
• Adoption of targeted therapies in clinical guidelines
• Biosimilars and biobetters like Hulio for providing affordable treatment
• Advancement in drug delivery
• Homecare administration.
   

Arthritis Monoclonal Antibodies Market Dynamics

Driving Factors: Increasing prevalence of autoimmune diseases and advancement in biotechnology & genetic engineering are driving growth in the arthritis monoclonal antibodies market

Increasing incidences of autoimmune diseases and advancements in biotechnology and genetic engineering drive the growth of the arthritis monoclonal antibodies market. Autoimmune diseases are interpreted to affect approximately one in ten individuals, and the burden continues to increase over time at varying rates. Biotechnology advancements, such as the development of human like antibodies for reducing immune responses, improving production through techniques such as phage display and transgenic animals, aid in propelling market growth. Further, genetic engineering enables modifications of structure, improving efficacy, reducing immunogenicity, and enabling novel applications.

 

Restrain Factors: The arthritis monoclonal antibodies market faces challenges due to the increased cost of monoclonal antibody therapies and strict regulations

The high cost of monoclonal antibody therapies is impacting their adoption, especially in emerging economies, which is hampering the market. Stringent regulations associated with monoclonal antibody manufacturing, due to their complex biological nature, slow down the market growth.

 

Opportunity: Increasing R&D efforts for discovering novel monoclonal antibodies are creating new opportunities in the arthritis monoclonal antibodies market

An increasing research and development activities for discovering novel monoclonal antibodies, driven by the advancements in drug formulation and delivery methods, is escalating market growth opportunities. Further, strategic collaborations and partnerships are needed to expedite the development of more effective next generation therapies with fewer side effects.

 

Challenges: In the arthritis monoclonal antibodies market, intense competition between key players

Despite its potential, the arthritis monoclonal antibodies market struggles with several obstacles. The intense competitive landscape between numerous players and continuous demand for innovation to stay ahead in the market leads to driving substantial investment, which ultimately impacts the market growth.

 

Global Arthritis Monoclonal Antibodies Market Ecosystem Analysis

The Global Arthritis Monoclonal Antibodies Market ecosystem includes drug manufacturers, research institutions, and healthcare providers. Key technologies involve advancements in antibody engineering, humanization techniques, and AI automation for accelerating drug development. Market growth is driven by the increasing prevalence of autoimmune diseases and the advancement in biotechnology & genetic engineering, while stringent regulations, high costs, and intense competition remain challenges. Opportunities lie in increasing R&D efforts for discovering novel monoclonal antibodies.

 

Global Arthritis Monoclonal Antibodies Market, By Type

The Humira segment led the arthritis monoclonal antibodies market, generating the largest market share. This dominance can be attributed to the increasing prevalence of autoimmune diseases, including rheumatoid arthritis and psoriasis. Humira is a formulation of a fully human anti TNF monoclonal antibody, which is a protein that plays a central role in the inflammatory response.

The Remicade segment in the arthritis monoclonal antibodies market is expected to grow at a significant CAGR over the forecast period, driven by its potential applications in treating conditions like psoriasis. Infliximab (Remicade) is a biological monoclonal antibody drug that stimulates the body’s immune system and treats certain diseases.  

 

Global Arthritis Monoclonal Antibodies Market, By Application

The rheumatoid arthritis segment held the largest market share in the arthritis monoclonal antibodies market, due to the launch of novel drug therapies and the prevalence of rheumatoid arthritis. Approved drugs for rheumatoid arthritis, such as adalimumab, infliximab, and rituximab, aid in suppressing inflammation, improving symptoms, and slowing joint damage.

The psoriatic arthritis segment in the arthritis monoclonal antibodies market is projected to register the fastest CAGR, driven by the increasing need for personalized therapies and the emergence of biosimilars. mAbs biologics help with joint pain and rashes caused by psoriatic arthritis.

 

North America is expected to account for the largest share of the arthritis monoclonal antibodies market during the forecast period, driven by the growing prevalence of arthritis, especially among the aging population. Further, the emergence of advanced therapies, including mAbs (monoclonal antibodies) for treating rheumatoid arthritis and osteoarthritis, is propelling market growth. Additionally, substantial government investments in R&D, enhancing innovation and improving treatment options, result in promoting the arthritis monoclonal antibodies market.

 

The United States is experiencing steady growth in the arthritis monoclonal antibodies market, fueled by strategic collaborations and partnerships for developing monoclonal antibodies. Further, clinical developments, regulatory approvals, and market penetration strategies facilitating rapid adoption of innovative biologics are supporting market growth.

 

Asia Pacific is expected to grow at the fastest CAGR in the arthritis monoclonal antibodies market during the forecast period. This rapid growth is driven by the robust ecosystem for the adoption of cutting-edge biologics, in order to develop and utilize monoclonal antibodies. Further, the growing healthcare investments, aging population, and increasing awareness about autoimmune disorders, including arthritis, are promoting the market.

 

Japan is rapidly expanding in the arthritis monoclonal antibodies market, due to the presence of an advanced healthcare infrastructure in the country. Further, government support for providing healthcare infrastructure and funds for carrying out research and development on a large scale, contributes to driving the market.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the arthritis monoclonal antibodies market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

WORLDWIDE TOP KEY PLAYERS IN THE ARTHRITIS MONOCLONAL ANTIBODIES MARKET INCLUDE

• Johnson & Johnson
• Roche
• Novartis
• Pfizer Inc.
• AbbVie Inc.
• Amgen Inc.
• Genentech
• GSK
• AstraZeneca PLC
• Mylan N.V.
• Hoffmann La Roche Ltd.
• Sanofi SA
• Daiichi Sankyo Company Ltd.
• Eli Lilly and Company
• Sigma Aldrich Co. LLC
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value Added Resellers (VARs)

 

Product Launches in Arthritis Monoclonal Antibodies

• In September 2025, Zoetis Inc. announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) had adopted a positive opinion recommending the granting of marketing authorization for Portela (relfovetmab), a new monoclonal antibody therapy intended for the alleviation of pain associated with osteoarthritis (OA) in cats.
• In May 2023, Officials with the FDA approved bedinvetmab injection (Librela; Zoetis) for the control of pain associated with osteoarthritis (OA) in dogs.
• In May 2023, Abiogen Pharma S.p.A., an Italian leading company in the field of osteoarticular and bone metabolism diseases, announced the acquisition of a 97.09% stake in EffRx Pharmaceuticals SA.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the arthritis monoclonal antibodies market based on the below mentioned segments: 

 

Global Arthritis Monoclonal Antibodies Market, By Type

• Humira
• Remicade
• Enbrel
• Rituxan
• Others

 

Global Arthritis Monoclonal Antibodies Market, By Application  

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Fibromyalgia
• Others

 

Global Arthritis Monoclonal Antibodies Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa